
SAIC Stock Forecast & Price Target
SAIC Analyst Ratings
Bulls say
Science Applications Intl is benefiting from a clean beat-and-raise, with FQ2 revenue of $1.88b to $1.9b, about 5% organic growth, and stronger-than-expected adjusted EBITDA of $193m to $222m alongside FCF of $131m. Its Defense and Intelligence and Civilian segments both expanded, while normalized on-contract growth of 9% and an “off the charts” RPO coverage support confidence that award delays are easing and that the current-year outlook is well covered. The stock’s appeal is further supported by a multi-year margin improvement plan, including $150m of annual run-rate savings, mid-10% EBITDA margins next year, and a path to about 11% in FY30, all while management raised FY27 EBITDA and EPS guidance.
Bears say
Science Applications Intl is viewed negatively because the Vanguard/Evolve recompete and RITS roll-off create near-term volatility while also threatening FY28 revenue, with initial task orders not expected until FY27 and annual comp effects hitting F1Q28 and F2Q28. Despite a $65M-$70M F2Q revenue tailwind from the delayed roll-off, the company is still expected to post only flattish y/y revenue growth in FY28 versus Street +1.5%, reflecting weak organic momentum. Its less attractive contract mix, relatively high leverage, slower-growth and lower-margin profile, and heavy dependence on U.S. government spending and procurement outcomes all support continued underperformance versus Government Services peers.
This aggregate rating is based on analysts' research of Science Applications International and is not a guaranteed prediction by Public.com or investment advice.
SAIC Analyst Forecast & Price Prediction
Start investing in SAIC
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Science Applications International (SAIC) Forecast
SAIC Analyst Forecast & Price Prediction
Start investing in SAIC
Order type
Buy in
Order amount
Est. shares
0 shares